ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Erasable FAP Targeted Spray-On Probe for Fluorescence-Guided Surgery.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Fluorescence-guided surgery is an emerging clinical field that aims to improve cancer detection in real-time, enabling spot-on therapeutic decisions. The use of fluorescent affinity probes has primarily involved systemically injected probes and, more recently, "spray-on probes". A current challenge has been to develop "turn-off" probes that can be inactivated by a UV light pulse and reduce background noise during iterative decision-making. Here, we report on the first development of a FAP-targeted erasable spray-on probe (ESOP). The probe consists of three components: (i) a highly bright, yellow light-emitting rhodamine dye, (ii) a photo-responsive linear triazene linker, and (iii) a FAP affinity ligand. We demonstrate that this probe could enable highly sensitive tumor-specific margin visualization within minutes after a spray-on application. Moreover, we show that the fluorescent signals could be fully erased with a 2-min UV-light pulse in tissue, permitting iterative staining applications with consistently high tumor-to-background ratios (TBRs). ESOP targeted against cancer or host tissue is feasible and is likely to yield transformative impacts on next-generation cancer surgeries, ultimately improving patient care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.